ST-segment Elevation as an AF Endophenotype

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look for a similarity in people's genes that may help understand which people could benefit from certain drugs for the treatment of atrial fibrillation (AF).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Procainamide

Criteria

Inclusion Criteria:

• 18 years of age or older

• Undergoing AF ablation at Vanderbilt or MGH

Exclusion Criteria:

• Patients taking membrane active anti-arrhythmic drugs with sodium channel blocking properties (amiodarone, dronedarone, flecainide, propafenone) at the time of the ablation

• Patients with a history of Brugada syndrome or type 1 Brugada ECG pattern on the baseline ECG

• Patients with a history of drug-induced torsades de pointes

• Patients with a known history of hypersensitivity to procainamide, procaine or related drugs

• Patients with a history of systemic lupus erythematosus and myasthenia gravis

• Patients with a history of second degree AV block (Mobitz type II) or third degree AV block

• Women of child-bearing potential unless post-menopausal, surgically sterile, or have a negative pregnancy test day on the day of procedure

• Patients with dual chamber pacemakers or implantable defibrillators requiring ventricular pacing (uninterpretable ECG)

• Patients unable to give informed consent